Revenue tied to Lilly’s Zepbound and Mounjaro more than doubles from the same period last year.

Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales ...

Surging consumer demand for blockbuster weight-loss drugs helped offset their declining prices.

Learn more Eli Lilly raised its full-year 2026 revenue guidance to between $82 billion and $85 billion after first-quarter ...

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

Eli Lilly said its tirzepatide franchise had another stellar quarter.

Eli Lilly alleged that Empower lured customers away from their brand-name GLP-1 products and toward the pharmacy's ...

The Indianapolis-based drugmaker reported profit of $7.4 billion for the first quarter, up from $2.8 billion in the same period a year earlier.

CNBC’s Angelica Peebles and Eli Lilly CEO David Ricks join 'Squawk Box' to discuss the company's quarterly earnings results, ...

Eli Lilly beats Q1 estimates and raises 2026 revenue outlook to $82–$85 billion. Mounjaro and Zepbound drive strong sales ...

Pharma major says seized fake Mounjaro in Gurugram did not originate from its supply chain, urges vigilance and purchase only ...

After just a few weeks on the market, thousands are already on Foundayo, Eli Lilly's oral weight loss pill. The drugmaker is ...